Israel’s Azura Ophthalmics announced positive three-month efficacy and safety results from its phase 2b study on its keratolytic eye preparation AZR-MD-001 0.5% in meibomian gland dysfunction (MGD).
Designed by New Zealand optometrist and entrepreneur Paul Rose for post-surgery patients, a new contact lens for irregular corneas, the Rose K2 XL oblate, has been unveiled by Menicon.
An independent inquiry into the workplace culture at Blind and Low Vision New Zealand (BLVNZ), found an already poor culture was made worse by the transformation work initiated in 2019, but is now improving thanks to organisational and policy change.
A new survey by the Australia and New Zealand Child Myopia Working Group found 28% of New Zealand’s under-18s have never visited an optometrist for an eye check – a figure unchanged since a similar 2018 survey.
It was great to be able to attend this in-person Australian & New Zealand Strabismus Society (ANZSS) meeting and catch up with colleagues from around the country after the last couple of years of Covid disruptions. The large group of attendees happily generated lots of discussion throughout the
Aldeyra has announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate for the treatment
The Optometrists and Dispensing Opticians Board (ODOB, the Board) of New Zealand has received a lot of interest regarding the complaint from the Royal Australian and New Zealand College of Ophthalmologists (RANZCO) about the Board’s approved and gazetted ‘Specialist optometrist scope of practice – o
The US Food and Drug Administration (FDA) has set out proposals for a New Alternative Methods Program to focus on replacing, reducing and refining the use of laboratory animals through the adoption of
Researchers at the Swiss technical university École polytechnique fédérale de Lausanne (EPFL) have developed a prototype device which flags deterioration of retinal pigment epithelial (RPE) cells to
A large Chinese and Australian study found middle-aged and older UK individuals with hyperopia, independent of genetic predisposition, had an increased risk of clinically significant depression
Safety and efficacy of AGN-190584 (Vuity drops) in individuals with presbyopia – the GEMINI 1 phase 3 randomised clinical trial
Authors of an international study of 38,694 European adults found the use of antidiabetic and lipid-lowering drugs (LLD) is associated with reduced prevalence of age-related macular degeneration (AMD) in the general population.
